{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:48:13Z","timestamp":1794941293743,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81760618"],"award-info":[{"award-number":["No. 81760618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Expanded and Applied Project of Appropriate Technology of Medicine and Health in Guangxi","award":["No. S201682"],"award-info":[{"award-number":["No. S201682"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Tuberculosis (TB) and Acquired Immune Deficiency Syndrome (AIDS) are leading causes of death globally. However, little is known about the long-term mortality risk and the timeline of death in those co-infected with human immunodeficiency virus (HIV) and\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB). This study sought to understand the long-term mortality risk, factors, and the timeline of death in those with HIV-\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) coinfection, particularly in those with insufficient TB treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TB-cause specific deaths were classified using a modified \u2018Coding of Cause of Death in HIV\u2019 protocol. A longitudinal cross-registration-system checking approach was used to confirm HIV\/MTB co-infection between two observational cohorts. Mortality from the end of TB treatment (6\u2009months) to post-treatment year (PTY) 5 (60\u2009months) was investigated by different TB treatment outcomes. General linear models were used to estimate the mean mortality at each time-point and change between time-points. Cox\u2019s proportional hazard regressions measured the mortality hazard risk (HR) at each time-point. The Mantel-Haenszel stratification was used to identify mortality risk factors. Mortality density was calculated by person year of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end point, mortality among patients with HIV\/MTB coinfection was 34.7%. From the end of TB treatment to PTY5, mortality and loss of person years among individuals with TB treatment failure, missing, and adverse events (TBFMA) were significantly higher than those who had TB cure (TBC) and TB complete regimen (TBCR). Compared to individuals with TBC and with TBCR, individuals with TBFMA tended to die earlier and their mortality was significantly higher (HR\n                      <jats:sub>TBFMA-TBC<\/jats:sub>\n                      \u2009=\u20093.0, 95% confidence interval: 2.5\u20133.6, HR\n                      <jats:sub>TBFMA-TBCR<\/jats:sub>\n                      \u2009=\u20092.9, 95% CI: 2.5\u20133.4,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Those who were na\u00efve to antiretroviral therapy, were farmers, had lower CD4 counts (\u2264200 cells\/\u03bcL) and were\u2009\u2265\u200950\u2009years of age were at the highest risk of mortality. Mortality risk for participants with TBFMA was significantly higher across all stratifications except those with a CD4 count of \u2264200 cells\/\u03bcL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Earlier and long-term mortality among those with HIV\/MTB co-infection is a significant problem when TB treatment fails or is inadequate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05527-0","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T06:04:15Z","timestamp":1606111455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Insufficient tuberculosis treatment leads to earlier and higher mortality in individuals co-infected with HIV in southern China: a cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhigang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Nehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-1263","authenticated-orcid":false,"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"5527_CR1","volume-title":"Global tuberculosis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. (DB\/OL). License: CC BY-NCSA 3.0 IGO. (http:\/\/www.who.int\/tb\/publications\/global_report\/en\/)."},{"key":"5527_CR2","volume-title":"Global tuberculosis report 2015","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization; 2015. (DB\/OL)."},{"key":"5527_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJM198903023200901","volume":"320","author":"PA Selwyn","year":"1989","unstructured":"Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545. https:\/\/doi.org\/10.1056\/NEJM198903023200901.","journal-title":"N Engl J Med"},{"key":"5527_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1164\/rccm.200405-590OC","volume":"170","author":"EL Corbett","year":"2004","unstructured":"Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170:673. https:\/\/doi.org\/10.1164\/rccm.200405-590OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5527_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/aje\/kwk116","volume":"165","author":"H L\u00f3pez-Gatell","year":"2007","unstructured":"L\u00f3pez-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007;165:1134. https:\/\/doi.org\/10.1093\/aje\/kwk116.","journal-title":"Am J Epidemiol"},{"key":"5527_CR6","first-page":"225","volume":"5","author":"M Badri","year":"2001","unstructured":"Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis. 2001;5:225. 11326821.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5527_CR7","unstructured":"WHO HIV\/AIDS Programme. Antiretroviral therapy for HIV infection adults and adolescents: recommendations for a public health approach (2010 revision) [R]. 2010. 21\u201324."},{"key":"5527_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/infdis\/jit368","volume":"208","author":"S Ravimohan","year":"2013","unstructured":"Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Makutu DK, Nfanyana K, et al. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. J Infect Dis. 2013;208:1784\u201393.","journal-title":"J Infect Dis"},{"key":"5527_CR9","doi-asserted-by":"publisher","unstructured":"Gao L, Zhou F, Li X, Jin Q. HIV\/TB co-infection in mainland China: a meta-analysis. PLoS One 2010;5(5): e10736. https:\/\/doi.org\/https:\/\/doi.org\/10.1371\/journal.pone.0010736. Doi: 10.1371\/journal. pone.0064915.","DOI":"10.1371\/journal.pone.0010736"},{"key":"5527_CR10","doi-asserted-by":"publisher","unstructured":"Ji Y, Wang Z, Shen J, Chen J, Yang J, Qi T, et al. Trends and characteristics of all-cause mortality among HIV-infected inpatients during the HAART era (2006\u20132015) in Shanghai, China. Biosci Trends. 2017;11(1):62\u201368. https:\/\/doi. org\/https:\/\/doi.org\/10.5582\/bst.2016.01195.","DOI":"10.5582\/bst.2016.01195"},{"key":"5527_CR11","doi-asserted-by":"publisher","unstructured":"Zheng ZG, Geng WK, Lu ZZ, Li JJ, Zhou CX, Yang WM. Impact on mortality of human immunodeficiency virus and Mycobacterium tuberculosis co-infection, Guangxi Zhuang Autonomous Region, 2011. Chin J Epidemiol, 2018;39(2):124\u2013127. https:\/\/doi. org\/https:\/\/doi.org\/10.5582\/bst.2016.01195.","DOI":"10.5582\/bst.2016.01195"},{"issue":"9","key":"5527_CR12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/QAD.0b013e3283390dd1","volume":"24","author":"SD Lawn","year":"2010","unstructured":"Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a south African cohort using an intensive pretreatment screening strategy [J]. AIDS. 2010;24(9):1323\u20138.","journal-title":"AIDS"},{"key":"5527_CR13","unstructured":"Zheng ZG, Cui ZZ, Huang MY, Pan DX. Effect of antiretroviral therapy in reducing deaths among patients co-infected with Mycobacterium tuberculosis and human immunodeficiency virus in Guangxi. Chin J Epidemiol. 2015;36(2):124\u2013127. https:\/\/DOI:10.3760\/ cma.j.issn. 0254\u20136450.2015.02.005."},{"key":"5527_CR14","doi-asserted-by":"crossref","unstructured":"Jouanguy E, Lamhamedi-Cherradi S, Altare F, Fondaneche MC, Tuerlinckx D, Blanche S, et al. Partial interferon gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 1997;100:2658\u20132664. [PubMed: 9389728].","DOI":"10.1172\/JCI119810"},{"key":"5527_CR15","doi-asserted-by":"publisher","first-page":"e47542","DOI":"10.1371\/journal.pone.0047542","volume":"7","author":"EB Wong","year":"2012","unstructured":"Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One. 2012;7:e47542.","journal-title":"PLoS One"},{"key":"5527_CR16","doi-asserted-by":"crossref","unstructured":"Greenberg AE, Lucas S, Tossou O, Coulibaly IM, Coulibaly D, Kassim S, Ackah A, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d\u2019Ivoire, AIDS 1995;9:1251\u20131254. [PubMed: 8561978].","DOI":"10.1097\/00002030-199511000-00006"},{"key":"5527_CR17","doi-asserted-by":"crossref","unstructured":"Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42:464\u2013469. [PubMed: 16810113].","DOI":"10.1097\/01.qai.0000225729.79610.b7"},{"key":"5527_CR18","doi-asserted-by":"crossref","unstructured":"Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O\u2019Rie T, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load J Immunol 2011;187:2222\u20132232. [PubMed: 21775682].","DOI":"10.4049\/jimmunol.1101122"},{"key":"5527_CR19","unstructured":"Zheng ZG, Tang ZZ, Lu QL, Wei H, Geng WK. Influential factors analysis on the survival time of patients infected with tuberculosis and HIV. Chin J Prev Med 2015;49(10):907\u2013913, https:\/\/DOI: 10.3760\/cma.j.issn.0253\u20439624.2015.10.014."},{"key":"5527_CR20","doi-asserted-by":"crossref","unstructured":"Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, et al. Risk factors affecting the mortality of HIV infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China. Infect Dis Poverty. 2018;7:25. https:\/\/doi.org\/10.1186\/s40249\u2013018-0405-8.","DOI":"10.1186\/s40249-018-0405-8"},{"key":"5527_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","volume":"8","author":"G Meintjes","year":"2008","unstructured":"Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516\u201323. https:\/\/doi.org\/10.1016\/S1473-3099(08)70184-1.","journal-title":"Lancet Infect Dis"},{"key":"5527_CR22","unstructured":"WHO. Treatment of Tuberculosis: Guidelines, Fourth Edition. 4th ed. 2010."},{"key":"5527_CR23","doi-asserted-by":"publisher","unstructured":"Sharma SK, Turaga KK, Balamurugan A, Saha PK, Pandey RM, Jain NK, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: A case-control study. Infect Genet Evol. 2003; 3: 183\u2013188. doi: https:\/\/doi.org\/10.1016\/S1567-1348(03)00086-8 PMID: 14522182.","DOI":"10.1016\/S1567-1348(03)00086-8"},{"key":"5527_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2471\/BLT.06.038331","volume":"85","author":"IY Gelmanova","year":"2007","unstructured":"Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Heal Organ. 2007;85:703\u201311. https:\/\/doi.org\/10.2471\/BLT.06.038331.","journal-title":"Bull World Heal Organ"},{"key":"5527_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jinf.2011.01.003","volume":"62","author":"NJ Saunders","year":"2011","unstructured":"Saunders NJ, Trivedi UH, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Deep resequencing of serial sputum isolates of mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect. 2011;62:212\u20137. https:\/\/doi.org\/10.1016\/j.jinf.2011.01.003.","journal-title":"J Infect"},{"key":"5527_CR26","doi-asserted-by":"crossref","unstructured":"Naidoo K, Yende-Zuma N, Padayatchi N, Jithoo N, Nair G, Bamber S, Gengiah S, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012;157:313\u2013324. [PubMed: 22944873].","DOI":"10.7326\/0003-4819-157-5-201209040-00004"},{"key":"5527_CR27","doi-asserted-by":"crossref","unstructured":"Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, et al. Paradoxical tuberculosis associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013;27:2577\u20132586. [PubMed: 24096631].","DOI":"10.1097\/01.aids.0000432456.14099.c7"},{"issue":"4","key":"5527_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QAI.0000000000000030","volume":"65","author":"AF Luetkemeyer","year":"2014","unstructured":"Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000000030.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5527_CR29","doi-asserted-by":"crossref","unstructured":"Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006;20:F1\u2013F7. [PubMed:16511406].","DOI":"10.1097\/01.aids.0000202648.18526.bf"},{"key":"5527_CR30","doi-asserted-by":"crossref","unstructured":"Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gamma delta T cells. J Immunol 2009;183:3915\u20133923. [PubMed: 19726768].","DOI":"10.4049\/jimmunol.0804020"},{"key":"5527_CR31","doi-asserted-by":"crossref","unstructured":"Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008;178:1083\u20131089. [PubMed: 18755923].","DOI":"10.1164\/rccm.200806-858OC"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05527-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T21:40:37Z","timestamp":1618436437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05527-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5527"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05527-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26357\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-26357\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cohort data were extracted from the China National HIV and TB Program registration databases and analyzed retrospectively and anonymously. Informed consent forms were also signed by patients before they were tested for HIV or screened for TB. Written data use consent forms were signed by patients from the beginning of confirmation of HIV positive status.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"873"}}